Celltrion Pharm Hosts Online Seminar on Remsima SC... "Effective for Switching Therapy as Well"

Remsima SC (Photo by Celltrion Pharm)

[Asia Economy Reporter Kim Ji-hee] Celltrion Pharm announced on the 10th that it held the 'RemsimaSC (active ingredient infliximab) Ontact Academy' on the 9th to share the latest information related to autoimmune disease treatment.

RemsimaSC is the world's first infliximab treatment developed by changing the existing intravenous injection formulation of Remsima to a subcutaneous injection formulation. It is used for the treatment of patients with inflammatory bowel disease (IBD), rheumatoid arthritis (RA), and ankylosing spondylitis (AS).

The event, held in the form of an online seminar, featured Professor Laurent Peyrin-Biroulet of Nancy University Hospital in France, president of the European Crohn's and Colitis Organisation (ECCO), as the main speaker, who gave a lecture on the topic of 'Switching to infliximab SC in patients with inflammatory bowel disease.'

The lecture presented pharmacokinetic and efficacy results of RemsimaSC compared to the intravenous (IV) formulation of Remsima in global clinical trials, along with actual switching treatment results of RemsimaSC conducted at a hospital in France, drawing attention. The main content of the presentation showed that patients administered RemsimaSC exhibited stable and higher blood drug concentrations compared to those receiving intravenous injections. In particular, patients who switched from intravenous injection to subcutaneous injection at week 30 during RemsimaSC switching showed increased blood concentrations to levels comparable to those receiving subcutaneous injections.

Professor Laurent emphasized that RemsimaSC can maintain consistent drug exposure and high blood concentrations even in actual switching treatment, which is effective in reducing immunogenicity. The switching treatment data will be published separately in a paper.

Professor Laurent stated, “Based on global clinical results and real-world switching treatment data, we have established an opportunity to confirm how effective RemsimaSC is in treating IBD indications. Besides pharmacokinetic and efficacy results, RemsimaSC is expected to provide convenience to many patients and medical staff as a new option by minimizing hospital visits and enabling relatively simple drug administration during the special situation of the COVID-19 pandemic.”

A Celltrion Pharm official said, "Since RemsimaSC has proven its efficacy and safety through various clinical trials and actual prescriptions, we will strive to establish it quickly in Korea as well," adding, "We plan to meticulously manage all aspects, from drug supply to feedback from medical sites, to ensure no inconvenience in prescriptions by medical staff and use by patients."

This content was produced with the assistance of AI translation services.